All Studies Meta Analysis Recent:

The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness

Zubair et al., Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2022.2062

Jan 2022

Post
Facebook

Source PDF All Meta

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020

^*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.

Lower risk for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19ivm.org

Retrospective 188 hospitalized patients in Pakistan, 90 treated with ivermectin, showing no significant differences with treatment. The ivermectin group had more severe disease (66% vs 58%, with 6x higher risk for severe disease patients), and more male patients (70% vs. 65%). Higher use of remdesivir and steroids in the ivermectin group also suggests that ivermectin was more likely to be given to patients in more severe condition. There were no side effects seen with ivermectin. Authors note that significantly improved ferritin levels were seen with treatment. Authors state that ivermectin patients received 2 12mg doses, 24 hours apart, but later state that the dosage was not standardized.

This is the 76th of 102 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 560 quintillion).

49 studies are RCTs, which show efficacy with p=0.00000038.

This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; unadjusted results with no group details.

Important missing comments or errors? Let us know.

risk of death, 9.0% higher, RR 1.09, p = 1.00, treatment 5 of 90 (5.6%), control 5 of 98 (5.1%), unadjusted.

hospitalization time, 8.0% higher, relative time 1.08, p = 0.40, treatment 90, control 98, unadjusted, Table 3, mean number of days.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Zubair et al., 18 Jan 2022, retrospective, Pakistan, peer-reviewed, 8 authors, study period October 2020 - February 2021, dosage 12mg single dose. Contact: muhammad.irfan@aku.edu.

This Paper Ivermectin All

The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness

Syed Muhammad Zubair, Muhammad Waleed Chaudhry, Ali Bin Sarwar Zubairi, Talha Shahzad, Aqusa Zahid, Ibrahim Ali Khan, Javaid Ahmed Khan, Muhammad Irfan

Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2022.2062

Role of ivermectin in hospitalized patients with mild to moderate COVID-19. To be presented as an 'e-poster' at virtual European Respiratory Society Congress 2021 on 07-09-2021.

References

Abbaspour, Hurrell, Kelishadi, Review on iron and its importance for human health, J Res Med Sci

Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ

Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis

Buonfrate, Salas-Coronas, Muñoz, Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial, Lancet Infect Dis

Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res

Camprubí, Almuedo-Riera, Martí-Soler, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PLoS One

Chaccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, doubleblind, placebo-controlled, randomized clinical trial, EClinicalMedicine

Chachar, Kahn, Asif, Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci

Drewe, Gutmann, Fricker, HIV protease inhibitor ritonavir: a more potent inhibitor of Pglycoprotein than the cyclosporine analog SDZ PSC 833, Biochem Pharmacol

Elgazzar, Abo Youssef, Hany, Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic

Galasso, Pons, Profeta, Gender differences in COVID-19 attitudes and behavior: Panel evidence from eight countries, Proc Natl Acad Sci

Gorial, Mashhadani, Sayaly, Effectiveness of ivermectin as add-on therapy in COVID-19 management (Pilot Trial), medRxiv

Haitao, Vermunt, Abeykoon, COVID-19 and sex differences: Mechanisms and biomarkers, Mayo Clin Proc

Hampton, Insight on sex-based immunity differences, with COVID-19 implications, JAMA

Hermine, Tharaux, Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial, JAMA Intern Med

Horby, Lim, Emberson, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med

Jin, Bai, He, Gender differences in patients with COVID-19: Focus on severity and mortality, Front Public Health

Kalil, Patterson, Mehta, Baricitinib plus remdesivir for hospitalized adults with Covid-19, N Engl J Med

Lepist, Phan, Roy, Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro, Antimicrob Agents Chemother

López-Medina, López, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial, JAMA

Mangia, Russo, Civitelli, say, and do not say

Okumuş, Demirtürk, Çetinkaya, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis

Oudit, Pfeffer, Plasma angiotensin-converting enzyme 2: novel biomarker heart failure with implications for COVID-19, Eur Heart J

Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, J Pharm Pharm Sci

Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for Covid-19 -Interim WHO solidarity trial results, N Engl J Med

Priel, Silberberg, Mechanism of ivermectin facilitation of human P2X4 receptor channels, J Gen Physiol

Rajter, Sherman, Fatteh, Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study, Chest

Ravikirti, Pattadar, Ivermectin as a potential treatment for mild to moderate COVID-19 -A double blind randomized placebo-controlled trial, medRxiv

Shakhsi, Nematollah, Peyman, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

Smit, Ochomo, Aljayyoussi, Human direct skin feeding versus membrane feeding to assess the mosquitocidal efficacy of high-dose ivermectin (IVERMAL Trial), Clin Infect Dis

Takahashi, Iwasaki, Sex differences in immune responses, Science

Tufan, Güler, Matucci-Cerinic, COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs, Turk J Med Sci

Vahidy, Pan, Ahnstedt, Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area, PLoS One

Wang, Lv, Ji, Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets, Virus Res

Wimmersberger, Coulibaly, Schulz, Efficacy and safety of ivermectin against trichuris trichiura in preschool-aged and school-aged children: A randomized controlled dose-finding trial, Clin Infect Dis

Yang, Atkinson, Wang, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res

Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res

Zhou, She, Wang, Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 novel coronavirus disease

Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0